On February 18, 2026 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, reported that multiple presentations featuring POSLUMA (flotufolastat F 18) will be presented at the upcoming ASCO (Free ASCO Whitepaper) 2026 Genitourinary Cancers Symposium (ASCO GU). The conference will be held in San Francisco, Calif., from February 26-28, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentations include results from the first intra-patient, head-to-head comparator study of urinary radioactivity between POSLUMA and piflufolastat F 18 in men with low prostate-specific antigen (PSA) biochemical recurrence following radical prostatectomy. Additional presentations will feature post-hoc analyses from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT and LIGHTHOUSE studies, evaluating the diagnostic performance of 18F-flotufolastat PET/CT in men with suspected biochemical recurrence and newly diagnosed prostate cancer. The presentations will include comparisons with baseline conventional imaging (BCI), as well as additional analyses focused on the assessment of bone metastases.

"At ASCO (Free ASCO Whitepaper) GU, we’re pleased to share new data offering deeper insights into the performance of POSLUMA across clinically important prostate cancer settings, including results from our head-to-head comparator study, as well as additional analyses in biochemical recurrence and newly diagnosed disease," said Marco Campione, President and CEO of Blue Earth Diagnostics. "These presentations reflect our ongoing commitment to advancing molecular imaging with high-quality evidence that can help inform clinical decision-making, particularly in scenarios where earlier or clearer detection may influence patient management. We look forward to engaging with the oncology community in San Francisco as the field continues to evolve."

Moderated poster presentation sessions will take place on Thursday, February 26, 2026 at 11:30 – 12:45 p.m. and 5:45 – 6:45 p.m. (PST) at the Hall of the George R. Moscone Convention Center, and will also be available On Demand.

Blue Earth Diagnostics invites participants at ASCO (Free ASCO Whitepaper) GU to attend the presentations below. Participants onsite are also invited to visit Blue Earth Diagnostics’ booth (#15). For full session details and scientific presentation listings, please see the ASCO (Free ASCO Whitepaper) GU online program here.

ASCO GU 2026 Scientific Presentations Featuring POSLUMA (Flotufolastat F 18)
DATE: Thursday, February 26, 2026
Title: An intra-patient contemporaneous comparison of 18F-piflufolastat and 18F-flotufolastat urinary radioactivity and local and pelvic region detection rates in men with low prostate-specific antigen biochemical recurrence of prostate cancer after radical prostatectomy
Presenter: Brian T. Helfand, MD, Endeavor Health, Glenview, Illinois
Session Type: Poster Presentation A13
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 32

DATE: Thursday, February 26, 2026
Title: Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc analysis from the phase 3 LIGHTHOUSE study
Presenter: Devaki Shilpa Surasi, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas
Session Type: Poster Presentation K3
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 311

DATE: Thursday, February 26, 2026
Title: Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging in men with biochemical recurrence of prostate cancer: descriptive post-hoc analysis from the Phase 3 SPOTLIGHT study
Presenter: Ashesh Jani, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
Session Type: Poster Presentation A11
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 30

DATE: Thursday, February 26, 2026
Title: Detection of bone metastases in men with low PSA biochemical recurrence of prostate cancer with 18F-flotufolastat PET/CT: A post-hoc analysis from the phase 3 SPOTLIGHT study
Presenter: Ashesh B. Jani, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
Session Type: Poster Presentation A12
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 31

DATE: Thursday, February 26, 2026
Title: Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy
Presenter: Rajesh Sehgal, MD, AdventHealth Cancer Institute Orlando, Orlando, Florida
Session Type: Poster Presentation A6
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 25

(Press release, Blue Earth Diagnostics, FEB 18, 2026, View Source [SID1234662763])